GV-971

DRUG5 trials

Sponsors

Shanghai Greenvalley Pharmaceutical Co., Ltd., Green Valley (Shanghai) Pharmaceuticals Co., Ltd., First Affiliated Hospital Xi'an Jiaotong University

Conditions

Alzheimer DiseaseAlzheimer's DiseaseBioavailabilityPharmacokineticsSafety

Phase 1

A Study to Assess the Bioavailability of Oral Sodium Oligo-mannurarate (GV-971) in Healthy Chinese Male Subjects

CompletedNCT02986529

Shanghai Greenvalley Pharmaceutical Co., Ltd.Bioavailability

Start: 2016-11-30End: 2017-11-30Updated: 2018-02-07

A Study to Assess the Safety and Pharmacokinetics of Oral Sodium Oligo-mannurarate (GV-971) in Healthy Chinese Subjects

Shanghai Greenvalley Pharmaceutical Co., Ltd.Pharmacokinetics, Safety

Start: 2018-10-15End: 2018-12-31Target: 45Updated: 2018-10-22

Phase 3

A Study of Sodium Oligomannate (GV-971) in Participants With Mild to Moderate Alzheimer's Disease

SuspendedNCT04520412

Green Valley (Shanghai) Pharmaceuticals Co., Ltd.Alzheimer Disease

Start: 2020-10-27End: 2026-10-31Target: 2046Updated: 2022-11-23

Phase 4

An Efficacy and Safety Study of Sodium Oligomannate (GV-971) for the Treatment of Alzheimer's Disease

RecruitingNCT05908695

Green Valley (Shanghai) Pharmaceuticals Co., Ltd.Alzheimer's Disease

Start: 2023-08-31End: 2029-12-31Target: 1312Updated: 2023-11-09

Unknown Phase

Efficacy and Safety of Donepezil and Sodium Oligomannate in Patients With Mild to Moderate Alzheimer's Disease

First Affiliated Hospital Xi'an Jiaotong UniversityAlzheimer Disease

Start: 2021-12-31End: 2024-12-31Target: 150Updated: 2021-11-10

Related Papers

Effect of masupirdine (SUVN‐502) on cognition in patients with moderate Alzheimer's disease: A randomized, double‐blind, phase 2, proof‐of‐concept study

Alzheimer s & Dementia Translational Research & Clinical Interventions2022-01-0127 citations

A Potential New Alzheimer’s Treatment That May Function by Modulating the Gut Microbiota

touchREVIEWS in Neurology2022-01-01